HBC Hofseth Biocare

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OILâ„¢ FOR PETS

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL™ FOR PETS

Hofseth BioCare ASA (“HBC”) pet care product Brilliant Salmon Oil™, a food and health supplement for dogs and cats, is now available in outlets across the UK, Spain, Iceland and online.

This retail distribution agreement with a global leading club store is an important milestone for HBC in its efforts for global distribution of Brilliant Salmon Oil™. The launch has started very successfully, and in-store incentive promotions will start at the end of the month to raise even more awareness. 

Kai Morten Thuen, Hofseth BioCare ASA’s Head of Sales & Marketing states, “This is an honor and great recognition for our company. We are thrilled to enter this retail agreement with one of the most well-renowned global retailers, known for their rigorous quality standards. It further accelerates our growth strategy for our pet care market flagship product, Brilliant Salmon Oil.”

Furthermore, in the last three months, HBC has signed up seven more distributors in the US and Canada, covering most of North America.  Brilliant Salmon Oil™ first entered a US store in April of this year and will be available in over 1,000 stores by the end of September. The speed of this success, despite a COVID-19 market slowdown, is seen as very encouraging and outpaces our expectations. 

About Brilliant Salmon Oil:

Brilliant Salmon Oil by Hofseth BioCare is produced in Norway using the purest process possible. Due to the unique patented extraction process – without boiling or pressing the oil – all the natural nutrients in the Atlantic Salmon are preserved. The whole process happening within hours, result in the purest and most transparent oil, completely free of additives. Brilliant contributes to shinier coat, softer paws, as well as helping to prevent cardiovascular disease. 

For further information, please contact:

Kai Morten Thuen, Head of Sales and Marketing at Hofseth BioCare ASA

Phone:

E-mail:

James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASA

Phone:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. The ingredients are in various stages of discovery and preclinical development in collaboration with multiple clinics and university research labs in several countries. Lead preclinical and clinical candidates are in development toward treatment for iron-deficiency anaemia, Gastro-Intestinal Inflammation (NEC/IBS/UC), prediabetes, age-related sarcopenia and osteoarthritis.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare



This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

EN
27/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: Annual General Meeting completed Hofseth BioCare ASA held its Annual General Meeting on 23 May 2025. All proposals were resolved as presented in the notice issued on 2 May 2025. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: E-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by takin...

 PRESS RELEASE

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting a 15% increase from Q1 2024 (NOK 52.1 million), driven by continued growth in higher-margin human and pet health segments, despite early-quarter production constraints and ongoing pressure in the commodity oil market. Cost of goods sold (CoGS) amounted to NOK 37.5 million, up from NOK 27.3 million in Q1 2024. Operating expenses total...

 PRESS RELEASE

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SP...

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon in the US. Branded as “Norwegian Salmon Oil”, it retains the complete balance and nutritional profile of fresh Atlantic salmon in a softgel format. Joining Garden of Life’s portfolio of health supplements available online, Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-grade salmon and provides whole-fish health benefits from its full spectrum of omegas. It differentiates from a competiti...

 PRESS RELEASE

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSEC...

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company") on 10 March 2025 regarding a contemplated bond issuance. The Company is pleased to announce that it has now successfully placed CHF-denominated unsecured bonds for a total amount of approximately CHF 3.5 million (the "Bonds"). The Bonds were subscribed for by investors in Switzerland and Liechtenstein. Settlement of the Bonds issue is expected to occur simultaneously as the issue date, which is expected to be on 5 M...

 PRESS RELEASE

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2025 The Annual General Meeting of Hofseth BioCare ASA for 2025 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 23 May 2025 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: About Hofseth BioCare ASA: Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch